New Report Available: China Metformin Market, 2010-2019

According to the statistics of International Diabetes Federation (IDF), in 2013, the prevalence of diabetes among adults aged from 20 to 79 was 8.3% and the number of diabetes patients has reached 382 million in the world, 80% of which come from middle income and low income countries and the figure demonstrates a fast rising trend. It is estimated that by 2035, there will be nearly 592 million people suffering from diabetes in the whole world. The number of diabetes patients in China was estimated to be 98.4 million in 2013, ranking first in the world, followed by India (65.1 million), USA (24.4 million), Brazil (11.9 million) and Russia (10.9 million). IDF estimates that by 2035, the number of diabetes patients in China will reach 143 million, still ranking first in the world while that in America will reach 29.7 million. The fast growth of diabetes in China and other developing countries has put a heavy burden on their social and economic development.
There are about 90 million diabetes patients in today's China and 95% of them suffer from type 2 diabetes mellitus. And the number of potential patients might reach up to 200 million.
As the first-line drug for the treatment of type 2 diabetes, metformin can prevent macroangiopathy and microangiopathy caused by diabetes, act positively on hyperinsulinemia and insulin resistence and lipid metabolism as well as slow down the progression of prediabetes to diabetes.
Although discovered as early as in 1929, metformin was neglected due to the prevalence of insulin. Later, insulin was found to have such problems as high incidence of severe hypoglycemia, weight gain and inconvenience. Interest in metformin picked up when it appeared in the French market after French physician Sterne published an article about it in 1957. However, influenced by the side effects of phenformin, metformin was once suggested to exit the market. Under the persistent exploration of scholars like Sterne, it is found that metformin has no inhibiting action on lactate release and oxidation and that it reports lower risk of lactic acidosis than other biguanide agents. And only when metformin got FDA's approval in 1995 did it begin to take the lead. United Kindom Prospective Diabetes Study spent 3 decades (2 decades of trial and one decade of follow-up visit) in proving the efficacy of metformin can reduce the rate of adverse cardiovascular outcomes in patients with type 2 diabetes especially overweight ones, which finally help metformin walk to the forefront of diabetes treatment.

Full Report Details at
- http://www.fastmr.com/prod/1020590_china_metformin_20102019.aspx?afid=301

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Type 2 Diabetes Therapeutics in Asia-Pacific Markets to 2020 - Increasing Uptake of Novel Drug Classes to Drive Market Growth
- Granules India Limited (GRANULES) - Financial and Strategic SWOT Analysis Review
- Depomed, Inc. (DEPO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Renal Insufficiency - Pipeline Review, H1 2015
- Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) - Financial and Strategic SWOT Analysis Review